Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel vs Hormone Therapy in mCRPC
NCT04139772Phase 3Unknown
- Sponsor
- National Cancer Institute
- Start
- Sep 2019
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Abiraterone Acetate Tablets (I), enzalutamide in metastatic castration-resistant prostate cancer (mCRPC), sponsored by National Cancer Institute. Status: unknown.
02
Drugs
Abiraterone Acetate Tablets (I)enzalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04139772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04139772.